NAD+: What the Evidence Actually Shows

The mechanistic story is straightforward and largely uncontested: NAD+ is required for mitochondrial energy production, NAD+ declines with age, so raising it should restore something. The uncontested part ends there. The open question is whether giving NAD+ from outside actually raises it inside the cells that matter, and whether doing so changes anything a person would notice. That is why most of the human research uses oral precursors rather than NAD+ itself — the molecule is large and charged, and precursors are the route researchers chose to raise cellular NAD+ reliably. A trial that gives NAD+ intravenously is testing a different proposition from one that gives a precursor by mouth, and neither is testing the claim printed on a wellness drip menu.^1,3,4

One randomized trial has tested NAD+ given by injection. It enrolled 180 adults with heart failure from ischemic cardiomyopathy — ejection fraction 45% or below, New York Heart Association class II to III — and gave them either intravenous NAD+ at 10 mg a day or a placebo for seven days, on top of guideline-directed medical therapy. At one month the NAD+ group's left ventricular ejection fraction was 45.44% against 42.44% on placebo, a statistically significant difference. Everything else was a trend that did not reach significance: NT-proBNP at day seven, the six-month composite of major adverse cardiac and cerebrovascular events, and improvement in NYHA class. The authors describe it as a single-center study warranting further validation in larger multicenter trials. The oral-precursor literature is much larger and points in a different direction — 32 randomized trials of nicotinamide riboside and 16 of nicotinamide mononucleotide, in populations including older adults with amnestic mild cognitive impairment, patients with Friedreich's ataxia, and older patients with diabetes.^1,2,3,4

There is one dose in the randomized injected-route record and it is 10 mg per day intravenously for seven days, given in hospital alongside standard heart-failure therapy. Nothing in the randomized literature establishes a dose, a schedule, a duration or a route for a healthy adult taking NAD+ for energy or aging, because no randomized trial has enrolled that person for that purpose. The oral precursor trials used their own doses of their own molecules, and those numbers do not transfer to an injection of a different compound. This page reports what the trials assigned. It is not dosing guidance, and anyone considering NAD+ should be having that conversation with a clinician who knows their history.¹

The randomized safety base for injected NAD+ is one seven-day trial in 180 hospitalized cardiac patients, which is a narrow foundation for describing the safety of repeated infusions or months of injections in healthy adults. What that trial does establish is that a short low-dose intravenous course was tolerated well enough in a monitored setting alongside standard therapy. What it cannot tell you is anything about long-term use, higher doses, subcutaneous self-injection, or the compounded preparations actually sold — whose sterility and potency depend entirely on the pharmacy that made them, since there is no FDA-approved NAD+ injection to compare against. The oral precursor trials carry their own safety data for their own molecules and routes. Reported effects during infusion, such as flushing or chest tightness when a drip runs quickly, come from clinical practice rather than from randomized evidence, and this page does not have a trial to cite for them.¹